Understand the source comparison
Pe-22-28 Safety Profile: Dosing and Tolerability Comparison
Different research applications require different dosing regimens, and safety margins vary accordingly. The table below summarizes observed effects and adverse events across dose ranges documented in peer-reviewed studies. 0.1–0.3 mg/kg Minimal to modest impro
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different research applications require different dosing regimens, and safety margins vary accordingly. The table below summarizes observed effects and adverse events across dose ranges documented in peer-reviewed studies.
- 0.1–0.3 mg/kg
- Minimal to modest improvement in spatial memory tasks
- None. Indistinguishable from saline controls in all toxicity panels
- 20–30 minutes; cleared within 2–3 hours
- +15–25% vs baseline
- Sub-therapeutic for most research models; may serve as control dose
- 0.5–1.0 mg/kg
- Robust enhancement in novel object recognition, Morris water maze, contextual fear conditioning
- No mortality, no organ toxicity, no immune response
- 20–30 minutes; no tissue accumulation
- +30–45% vs baseline
- Standard research dose; consistent cognitive benefit without detectable harm
- 2.0–5.0 mg/kg
- Cognitive enhancement similar to 1 mg/kg; no additional benefit observed
- Mild transient reduction in exploratory behaviour (resolved within 24 hours); no structural toxicity
- 20–30 minutes; enzymatic degradation unchanged
- +40–50% vs baseline (plateau effect)
- Supra-therapeutic; no added efficacy and mild behavioural suppression at upper range
- >5.0 mg/kg
- Not systematically evaluated in published literature
- Unknown. No peer-reviewed data available
- Presumed similar; metabolic saturation possible
- Unknown
- Not recommended; exceeds established safety window
- The data reveal a clear dose-response plateau: increasing dose above 1 mg/kg does not enhance cognitive outcomes but does introduce mild behavioural changes (reduced exploration, possibly reflecting sedation or malaise). This plateau is consistent with receptor saturation models. Once BDNF signaling and AMPA trafficking reach maximal enhancement, additional peptide provides no further benefit. The practical safety implication: there is no research justification for exceeding 1 mg/kg in animal models, and doing so increases risk without improving outcomes.